Reasons for Phosphate Binder Discontinuation Vary by Binder Type

Journal of Renal Nutrition

Volumn 24, Issue 2, 2014, Pages 105-109

  Wang, Steven ^a   Anum, Emmanuel A ^a   Ramakrishnan, Karthik ^a   Alfieri, Thomas ^a   Braunhofer, Peter ^b   Newsome, Britt ^c  

^a DAVITA CLINICAL RESEARCH   (United States)

^b Vifor (International) Inc   (Switzerland)

^c Denver Nephrology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID DERIVATIVE; CALCIUM ACETATE; CALCIUM DERIVATIVE; LANTHANUM; LANTHANUM CHLORIDE; PHOSPHATE; POLYAMINE; SEVELAMER;

ADULT; AGED; ARTICLE; BLOOD; CHRONIC KIDNEY FAILURE; DRUG EFFECT; FEMALE; GASTROINTESTINAL TRACT; HUMAN; HYPERCALCEMIA; HYPOPHOSPHATEMIA; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; PATHOLOGY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; TREATMENT OUTCOME; UNITED STATES;

ACETATES; ADULT; AGED; CALCIUM COMPOUNDS; FEMALE; GASTROINTESTINAL TRACT; HUMANS; HYPERCALCEMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE, CHRONIC; LANTHANUM; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PHOSPHATES; POLYAMINES; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84894259065     PISSN: 10512276     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jrn.2013.11.004     Document Type: Article

References (27)

1. Block G.A., Hulbert-Shearon T.E., Levin N.W., Port F.K. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998, 31:607-617.
2. Block G.A., Klassen P.S., Lazarus J.M., Ofsthun N., Lowrie E.G., Chertow G.M. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004, 15:2208-2218.
3. Kalantar-Zadeh K., Kuwae N., Regidor D.L., et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006, 70:771-780.
4. Menon V., Greene T., Pereira A.A., et al. Relationship of phosphorus and calcium-phosphorus product with mortality in CKD. Am J Kidney Dis 2005, 46:455-463.
5. Saran R., Bragg-Gresham J.L., Rayner H.C., et al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS. Kidney Int 2003, 64:254-262.
6. Tentori F., Blayney M.J., Albert J.M., et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2008, 52:519-530.
7. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003, 42(4 suppl 3):S1-S201.
8. Young E.W., Akiba T., Albert J.M., et al. Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2004, 44(5 suppl 2):34-38.
9. Benner D., Nissenson A.R., Van Wyck D. Focused clinical campaign improves mineral and bone disorder outcomes. J Ren Care 2012, 38:2-8.
10. Lopes A.A., Tong L., Thumma J., et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012, 60:90-101.
11. Arenas M.D., Malek T., Gil M.T., Moledous A., Alvarez-Ude F., Reig-Ferrer A. Challenge of phosphorus control in hemodialysis patients: a problem of adherence?. J Nephrol 2010, 23:525-534.
12. Karamanidou C., Clatworthy J., Weinman J., Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008, 9:2.
13. Schmid H., Hartmann B., Schiffl H. Adherence to prescribed oral medication in adult patients undergoing chronic hemodialysis: a critical review of the literature. Eur J Med Res 2009, 14:185-190.
14. Toussaint N.D., Pedagogos E., Beavis J., Becker G.J., Polkinghorne K.R., Kerr P.G. Improving CKD-MBD management in haemodialysis patients:barrier analysis for implementing better practice. Nephrol Dial Transplant 2011, 26:1319-1326.
15. Browne T., Merighi J.R. Barriers to adult hemodialysis patients' self-management of oral medications. Am J Kidney Dis 2010, 56:547-557.
16. Chiu Y.W., Teitelbaum I., Misra M., de Leon E.M., Adzize T., Mehrotra R. Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009, 4:1089-1096.
17. Wang S, Alfieri T, Ramakrishnan K, Braunhofer P, Newsome B. Serum phosphorus levels and pill burden are inversely associated with adherence in patients on hemodialysis Nephrol Dial Transplant. 2013. Epub 2013/09/07. doi: 10.1093/ndt/gft280. PubMed PMID: 24009281.
18. Finn W.F., Joy M.S. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Curr Med Res Opin 2005, 21:657-664.
19. Hutchison A.J., Barnett M.E., Krause R., Kwan J.T., Siami G.A. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 2008, 110:c15-c23.
20. Hutchison A.J., Maes B., Vanwalleghem J., et al. Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate. Nephron Clin Pract 2005, 100:c8-19.
21. Hutchison A.J., Maes B., Vanwalleghem J., et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006, 102:c61-c71.
22. Sprague S.M., Ross E.A., Nath S.D., Zhang P., Pratt R.D., Krause R. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clin Nephrol 2009, 72:252-258.
23. Arenas M.D., Rebollo P., Malek T., et al. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice. J Nephrol 2010, 23:683-692.
24. Sanofi-Aventis US LLC. Renvela® (sevelamer carbonate): US prescribing information. Accessed October 10,2013. http://www.renvela.com/%7E/media/RenvelaUS/Files/RV382_Renvela_PI_08.2011.pdf.
25. Shire US Inc. Fosrenol® (lanthanum carbonate): US prescribing information. Accessed October 10,2013. http://pi.shirecontent.com/PI/PDFs/Fosrenol_USA_ENG.pdf.
26. Sanofi-Aventis US LLC. Renagel® (sevelamer hydrochloride): US prescribing information. Accessed October 10,2013. http://www.renassist.com/media/pdf/GEN-Renagel%20PI%202011%20NEW.pdf.
27. Shire Pharmaceuticals Limited. Fosrenol® (lanthanum carbonate) oral powder: summary of product characteristics.Accessed October 10,2013. http://www.medicines.org.uk/EMC/medicine/26625/SPC/Fosrenol+750mg+%26+1000mg+oral+powder/.